Safety and Efficacy of Mesenchymal Stem Cells in COVID-19 Patients: A Systematic Review and Meta-analysis

Overview

Journal Immun Inflamm Dis

Specialties Allergy & Immunology
Infectious Diseases

Date 2023 Sep 29

PMID 37773722

Authors

Cai Yan

Minjie Hu

Rongjuan Dai

Affiliations

Soon will be listed here.

Abstract

Background: Coronavirus disease-19 (COVID-19) is a zoonotic disease that has become a global pandemic. The fast evolution of the COVID-19 pandemic and persist problems make COVID-19 highly infectious; publicly accessible literature and other sources of information continue to expand in volume. The mesenchymal stem cells (MSCs) therapy efficacy for COVID-19 is debatable.

Objective: This systematic review and meta-analysis (SRMA) aimed to evaluate the usefulness of MSCs in treating COVID-19.

Methods: Relevant publications were retrieved from databases up to April 30, 2022. In the case of dichotomous data, the 95% confidence intervals (CIs) and pooled risk ratio (RR) were estimated with a random effects model (REM) or fixed effects model (FEM). The pooled mean difference (MD) and 95% CIs were calculated with REM or FEM in continuous data. In the outcomes, studies with insufficient or unusable data were reported descriptively.

Results: A total of eight randomized controlled trials (RCTs) with 464 people were chosen for this SRMA. Relative to the control group, mortality was significantly lower in the MSCs group (RR: 0.66, 95% CI: 0.44, 0.99, Z = 2.01, p = .04); other secondary outcomes, such as the clinical symptom improvement rate improved in the MSCs group (RR: 1.44, 95% CI: 1.05, 1.99, Z = 2.24, p = .03), clinical symptom improvement time (MD: -4.01, 95% CI: -6.33, -1.68, Z = 3.38, p = .0007), C-reactive protein (CRP) (MD: -39.16, 95% CI: -44.39, -33.94, Z = 14.70, p < .00001) and days to hospital discharge (MD: -3.83, 95% CI: -6.19, -1.48, Z = 3.19, p = .001) reduced significantly in MSCs group. However, the adverse reaction incidence did not change significantly.

Conclusions: MSCs are a viable therapy option for COVID-19 because of their safety and potential efficacy. With no significant adverse effects, MSCs can reduce mortality, clinical symptom improvement time, and days to hospital discharge, improve clinical symptoms, and reduce inflammatory cytokines CRP in COVID-19. However, further high-quality clinical studies are required to confirm these results.

Citing Articles

Cell therapies for viral diseases: a new frontier.

Nardo D, Maddox E, Riley J Semin Immunopathol. 2025; 47(1):5.

PMID: 39747475 PMC: 11695571. DOI: 10.1007/s00281-024-01031-8.

Understanding Post-COVID-19: Mechanisms, Neurological Complications, Current Treatments, and Emerging Therapies.

Zambrano K, Castillo K, Penaherrera S, Vasconez H, Caicedo A, Gavilanes A Int J Gen Med. 2024; 17:6303-6321.

PMID: 39717071 PMC: 11664001. DOI: 10.2147/IJGM.S499905.

Safety and efficacy of mesenchymal stem cells in COVID-19 patients: A systematic review and meta-analysis.

Yan C, Hu M, Dai R Immun Inflamm Dis. 2023; 11(9):e1000.

PMID: 37773722 PMC: 10515507. DOI: 10.1002/iid3.1000.

References

Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Fotiou D, Migkou M, Tzanninis I . Emerging treatment strategies for COVID-19 infection. Clin Exp Med. 2020; 21(2):167-179. PMC: 7598940. DOI: 10.1007/s10238-020-00671-y. View

Majumder J, Minko T . Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. AAPS J. 2021; 23(1):14. PMC: 7784226. DOI: 10.1208/s12248-020-00532-2. View

Monsel A, Hauw-Berlemont C, Mebarki M, Heming N, Mayaux J, Nguekap Tchoumba O . Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial. Crit Care. 2022; 26(1):48. PMC: 8860258. DOI: 10.1186/s13054-022-03930-4. View

Ionescu L, Byrne R, van Haaften T, Vadivel A, Alphonse R, Rey-Parra G . Stem cell conditioned medium improves acute lung injury in mice: in vivo evidence for stem cell paracrine action. Am J Physiol Lung Cell Mol Physiol. 2012; 303(11):L967-77. PMC: 3532523. DOI: 10.1152/ajplung.00144.2011. View

Zhu R, Yan T, Feng Y, Liu Y, Cao H, Peng G . Mesenchymal stem cell treatment improves outcome of COVID-19 patients via multiple immunomodulatory mechanisms. Cell Res. 2021; 31(12):1244-1262. PMC: 8546390. DOI: 10.1038/s41422-021-00573-y. View

Ge X, Li J, Yang X, Chmura A, Zhu G, Epstein J . Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013; 503(7477):535-8. PMC: 5389864. DOI: 10.1038/nature12711. View

Akkoc T . COVID-19 and Mesenchymal Stem Cell Treatment; Mystery or Not. Adv Exp Med Biol. 2020; 1298:167-176. DOI: 10.1007/5584_2020_557. View

Tan M, Liu Y, Zhou R, Deng X, Li F, Liang K . Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology. 2020; 160(3):261-268. PMC: 7283723. DOI: 10.1111/imm.13223. View

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. PMC: 7159299. DOI: 10.1016/S0140-6736(20)30183-5. View

10.

Ventura-Carmenate Y, Alkaabi F, Castillo-Aleman Y, Villegas-Valverde C, Ahmed Y, Sanna P . Safety and efficacy of autologous non-hematopoietic enriched stem cell nebulization in COVID-19 patients: a randomized clinical trial, Abu Dhabi 2020. Transl Med Commun. 2021; 6(1):25. PMC: 8563822. DOI: 10.1186/s41231-021-00101-5. View

11.

Coomes E, Haghbayan H . Interleukin-6 in Covid-19: A systematic review and meta-analysis. Rev Med Virol. 2020; 30(6):1-9. PMC: 7460877. DOI: 10.1002/rmv.2141. View

12.

Yan C, Hu M, Dai R . Safety and efficacy of mesenchymal stem cells in COVID-19 patients: A systematic review and meta-analysis. Immun Inflamm Dis. 2023; 11(9):e1000. PMC: 10515507. DOI: 10.1002/iid3.1000. View

13.

Chen J, Hu C, Chen L, Tang L, Zhu Y, Xu X . Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection: A Hint for COVID-19 Treatment. Engineering (Beijing). 2020; 6(10):1153-1161. PMC: 7102606. DOI: 10.1016/j.eng.2020.02.006. View

14.

FRIEDENSTEIN A, PETRAKOVA K, Kurolesova A, Frolova G . Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968; 6(2):230-47. View

15.

Shi L, Huang H, Lu X, Yan X, Jiang X, Xu R . Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther. 2021; 6(1):58. PMC: 7873662. DOI: 10.1038/s41392-021-00488-5. View

16.

Lanzoni G, Linetsky E, Correa D, Cayetano S, Alvarez R, Kouroupis D . Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med. 2021; 10(5):660-673. PMC: 8046040. DOI: 10.1002/sctm.20-0472. View

17.

Tregoning J, Flight K, Higham S, Wang Z, Pierce B . Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021; 21(10):626-636. PMC: 8351583. DOI: 10.1038/s41577-021-00592-1. View

18.

Gentile P, Sterodimas A . Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia. Expert Opin Biol Ther. 2020; 20(7):711-716. PMC: 7196919. DOI: 10.1080/14712598.2020.1761322. View

19.

Dilogo I, Aditianingsih D, Sugiarto A, Burhan E, Damayanti T, Sitompul P . Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: A randomized controlled trial. Stem Cells Transl Med. 2021; 10(9):1279-1287. PMC: 8242692. DOI: 10.1002/sctm.21-0046. View

20.

Rebelatto C, Senegaglia A, Franck C, Daga D, Shigunov P, Stimamiglio M . Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial. Stem Cell Res Ther. 2022; 13(1):122. PMC: 8935270. DOI: 10.1186/s13287-022-02796-1. View